No link between Merck's Gardasil and blood clots, study says

Merck's Gardasil HPV vaccine--FierceBiotech file photo
Merck's Gardasil

Worries over Gardasil's safety are just one of the issues that have hampered uptake of Merck's ($MRK) best-selling vaccine for HPV. But now, a study published in JAMA says patients need not worry about an increased risk of deadly blood clots--a.k.a. venous thromboembolism, or VTE--in the period after vaccination. Researchers in Denmark examined a database of 1,613,798 women, finding that those who received the vaccine averaged 0.126 clots per person per year, compared with a rate of 0.159 clots per person per year in those who did not receive it. More

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

Find out how PDA can help you succeed with custom solutions and training for your employees – at your facility, our facility, or virtually.

Iowa State University is working on a room-temp-stable nasal spray vaccine for COVID-19, and it recently tapped device maker Zeteo for support.

Pfizer's shot will go before an FDA expert panel on Dec. 10, with Moderna's review pegged for the 17th, Warp Speed chief Moncef Slaoui, Ph.D., said.